The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 12, 2021
Filed:
Jan. 11, 2017
Applicants:
Novartis Ag, Basel, CH;
Universität Zürich, Zürich, CH;
Inventors:
Natalia Arenas-Ramirez, Zürich, CH;
Iwan Beuvink, Basel, CH;
Onur Boyman, Küsnacht, CH;
Barbara Brannetti, Basel, CH;
Andreas Katopodis, Basel, CH;
Simone Popp, Basel, CH;
Catherine Regnier, Basel, CH;
Chao Zou, Basel, CH;
Assignee:
Universität Zürich, Zürich, CH;
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/24 (2006.01); C12N 5/10 (2006.01); C12N 15/63 (2006.01); C07K 14/55 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/246 (2013.01); C07K 14/55 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/74 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01);
Abstract
The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.